Literature DB >> 35530524

Identification of SARS-CoV-2 Neutralizing Antibody with Pseudotyped Virus-based Test on HEK-293T hACE2 Cells.

Constant Gillot1, Julien Favresse1,2, Vincent Maloteau1, Jean-Michel Dogné1, Jonathan Douxfils1,3.   

Abstract

Neutralizing antibodies (NAbs) are of particular importance because they can prevent binding of the receptor binding domain (RBD) of the spike protein (S protein) to the angiotensin-converting enzyme 2 (ACE2) receptor present at the surface of human cells, preventing virus entry into the host cells. The gold standard method for detection of NAbs is the plaque reduction neutralization test (PRNT). Based on the measurement of cell lysis due to viral infection, this test is able to detect antibodies that prevent cell infection (Muruato et al., 2020; Lau et al., 2021). This technique requires the use of live pathogens, i.e., SARS-CoV-2 in this case, and must be done in a biosafety level 3 (BL3) laboratory. In addition, it requires expensive installations, skillful and meticulous staff, and a high workload, which prevents its wide implementation even in research laboratories. A SARS-CoV-2 pseudovirus will express the S protein responsible for cell entrance, but will not express the pathogenic genetic material of the virus, making them less dangerous for laboratory staff and the environment. Graphic abstract.
Copyright © 2022 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  COVID-19; Immune response; Neutralizing antibody; Pseudo-type virus; SARS-CoV-2

Year:  2022        PMID: 35530524      PMCID: PMC9018432          DOI: 10.21769/BioProtoc.4377

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  6 in total

1.  Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020.

Authors:  Ranawaka Apm Perera; Chris Kp Mok; Owen Ty Tsang; Huibin Lv; Ronald Lw Ko; Nicholas C Wu; Meng Yuan; Wai Shing Leung; Jacky Mc Chan; Thomas Sh Chik; Chris Yc Choi; Kathy Leung; Kin Ho Chan; Karl Ck Chan; Ka-Chi Li; Joseph T Wu; Ian A Wilson; Arnold S Monto; Leo Lm Poon; Malik Peiris
Journal:  Euro Surveill       Date:  2020-04

2.  Neutralizing antibody titres in SARS-CoV-2 infections.

Authors:  Eric H Y Lau; Owen T Y Tsang; David S C Hui; Mike Y W Kwan; Wai-Hung Chan; Susan S Chiu; Ronald L W Ko; Kin H Chan; Samuel M S Cheng; Ranawaka A P M Perera; Benjamin J Cowling; Leo L M Poon; Malik Peiris
Journal:  Nat Commun       Date:  2021-01-04       Impact factor: 14.919

3.  Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay.

Authors:  Jianhui Nie; Qianqian Li; Jiajing Wu; Chenyan Zhao; Huan Hao; Huan Liu; Li Zhang; Lingling Nie; Haiyang Qin; Meng Wang; Qiong Lu; Xiaoyu Li; Qiyu Sun; Junkai Liu; Changfa Fan; Weijin Huang; Miao Xu; Youchun Wang
Journal:  Nat Protoc       Date:  2020-09-25       Impact factor: 13.491

4.  Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.

Authors:  Jianhui Nie; Qianqian Li; Jiajing Wu; Chenyan Zhao; Huan Hao; Huan Liu; Li Zhang; Lingling Nie; Haiyang Qin; Meng Wang; Qiong Lu; Xiaoyu Li; Qiyu Sun; Junkai Liu; Changfa Fan; Weijin Huang; Miao Xu; Youchun Wang
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

5.  A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation.

Authors:  Antonio E Muruato; Camila R Fontes-Garfias; Ping Ren; Mariano A Garcia-Blanco; Vineet D Menachery; Xuping Xie; Pei-Yong Shi
Journal:  Nat Commun       Date:  2020-08-13       Impact factor: 14.919

6.  Neutralizing Antibody Responses in COVID-19 Convalescent Sera.

Authors:  William T Lee; Roxanne C Girardin; Alan P Dupuis; Karen E Kulas; Anne F Payne; Susan J Wong; Suzanne Arinsburg; Freddy T Nguyen; Damodara Rao Mendu; Adolfo Firpo-Betancourt; Jeffrey Jhang; Ania Wajnberg; Florian Krammer; Carlos Cordon-Cardo; Sherlita Amler; Marisa Montecalvo; Brad Hutton; Jill Taylor; Kathleen A McDonough
Journal:  J Infect Dis       Date:  2021-01-04       Impact factor: 5.226

  6 in total
  2 in total

1.  Lung Transplant Recipients Immunogenicity after Heterologous ChAdOx1 nCoV-19-BNT162b2 mRNA Vaccination.

Authors:  Emilie Catry; Julien Favresse; Constant Gillot; Jean-Louis Bayart; Damien Frérotte; Michel Dumonceaux; Patrick Evrard; François Mullier; Jonathan Douxfils; François M Carlier; Mélanie Closset
Journal:  Viruses       Date:  2022-07-02       Impact factor: 5.818

2.  Vaccine-induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster.

Authors:  Julien Favresse; Constant Gillot; Jean-Louis Bayart; Clara David; Germain Simon; Loris Wauthier; Mélanie Closset; Jean-Michel Dogné; Jonathan Douxfils
Journal:  J Med Virol       Date:  2022-09-21       Impact factor: 20.693

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.